Improvement of Wearing‑Off Symptoms After Initiation of COMT Inhibitors in Parkinson’s Disease patients with early motor fluctuations: Results from the 12 months interim analysis of REONPARK Study
Objective: The REONPARK study is an observational study conducted in Spain aiming to evaluate COMT inhibitors (iCOMT) effectiveness and tolerability in alleviating motor complications associated…Improvement in Time Spent in OFF State and In the Functional Impact of Motor Fluctuations After Initiation with COMT Inhibitors in Parkinson’s Disease Patients with Early Wearing-Off: Results from the REONPARK Study
Objective: REONPARK study is an observational study conducted in Spain aimed at evaluating COMT inhibitors (iCOMT) tolerability and effectiveness in alleviating motor complications associated with…Opicapone Co-administration Allows Significant Flow Reduction in Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: A Real-World Case Series
Objective: To quantify infusion-flow reduction associated with concomitant use of opicapone in patients receiving LDp/CDp infusion and to describe dyskinesia and cutaneous tolerability outcomes during…Clinical Features and Trajectories Related to Entacapone Use in Parkinson’s Disease: insights from the French NS Park Cohort
Objective: This study aimed to provide real-life entacapone use in French PD expert centers, focusing on temporal trends, therapeutic positioning, and treatment persistence. Background: Optimizing…Opicapone as adjunct to levodopa in Chinese patients with Parkinson’s disease and wearing-off: a randomized, double-blind, placebo-controlled phase 3 trial
Objective: To evaluate the efficacy and safety of once-daily opicapone as adjunct to levodopa in Chinese patients with Parkinson’s disease (PD) and wearing-off, and to…Efficacy of Opicapone in Early Motor Fluctuations in Parkinson’s Disease: A Comparison of Early versus Later Initiation
Objective: This post-hoc analysis assessed the long-term outcomes of early initiation of opicapone in levodopa-treated patients with early wearing-off in Parkinson’s disease. Background: The best…Long-term Safety of Opicapone in Parkinson’s Disease Patients with First Signs of Wearing-off
Objective: This post-hoc analysis evaluated opicapone’ s long-term safety and tolerability in Parkinson’s patients with recently diagnosed fluctuations (≤2 years). Background: Opicapone is used to…Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide
Objective: To review the safety data of opicapone (OPC) after 10 years of worldwide marketing experience. Background: OPC, a third-generation COMT inhibitor, is approved as…Opicapone for Management of Sleep Disturbances in Parkinson’s Disease: Post-hoc Analysis of the OASIS trial in Patients With and Without Probable RBD
Objective: To evaluate opicapone’s effect on sleep disturbances, motor/non-motor symptoms and quality of life in Parkinson's disease (PD) patients with and without probable Rapid eye…Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: a Four-Year Real-Life Experience
Objective: To describe the improvement of motor complications in patients with advanced Parkinson’s Disease (APD) treated with Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG). Background: The continuous enteral…
- 1
- 2
- 3
- …
- 13
- Next Page »